{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:31Z","timestamp":1793948431354,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-23883-x","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T09:20:58Z","timestamp":1754990458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD"],"prefix":"10.1186","volume":"25","author":[{"given":"Jun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoli","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"7","key":"23883_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921\u201337.","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"23883_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","volume":"72","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2023;72(2):372\u201380.","journal-title":"Gut"},{"issue":"10","key":"23883_CR3","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s00392-023-02250-z","volume":"112","author":"C Roderburg","year":"2023","unstructured":"Roderburg C, Krieg S, Krieg A, Vaghiri S, Mohr R, Konrad M, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients. Clin Res Cardiol. 2023;112(10):1446\u201353.","journal-title":"Clin Res Cardiol"},{"key":"23883_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of Cause-Specific mortality in patients with advanced nonalcoholic fatty liver disease: A Multi-National cohort study. Gastroenterology. 2018;155:443\u2013e5717.","journal-title":"Gastroenterology"},{"issue":"1","key":"23883_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12664-020-01018-x","volume":"39","author":"SW Wong","year":"2020","unstructured":"Wong SW, Chan WK. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol. 2020;39(1):1\u20138.","journal-title":"Indian J Gastroenterol"},{"issue":"4","key":"23883_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","volume":"75","author":"R Younes","year":"2021","unstructured":"Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol. 2021;75(4):786\u201394.","journal-title":"J Hepatol"},{"issue":"6","key":"23883_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/hepr.13764","volume":"52","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatol Res. 2022;52(6):497\u2013507.","journal-title":"Hepatol Res"},{"issue":"5","key":"23883_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/jgh.14856","volume":"35","author":"DH Sinn","year":"2020","unstructured":"Sinn DH, Kang D, Chang Y, Ryu S, Cho SJ, Paik SW, et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study. J Gastroenterol Hepatol. 2020;35(5):833\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"23883_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.pcad.2020.02.010","volume":"63","author":"KA So-Armah","year":"2020","unstructured":"So-Armah KA, Lim JK, Lo Re V3rd, Tate JP, Chang CH, Butt AA, et al. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Prog Cardiovasc Dis. 2020;63(2):184\u201391.","journal-title":"Prog Cardiovasc Dis"},{"issue":"11","key":"23883_CR10","first-page":"1779","volume":"38","author":"NWS Chew","year":"2022","unstructured":"Chew NWS, Ng CH, Chan KE, Chee D, Syn N, Tamaki N, et al. FIB-4 predicts MACE and cardiovascular mortality in patients with nonalcoholic fatty liver disease. Can J Cardiol. 2022;38(11):1779\u201380.","journal-title":"Can J Cardiol"},{"issue":"3","key":"23883_CR11","doi-asserted-by":"publisher","first-page":"oeac030","DOI":"10.1093\/ehjopen\/oeac030","volume":"2","author":"Y Higashiura","year":"2022","unstructured":"Higashiura Y, Tanaka M, Mori K, Mikami T, Hosaka I, Ohnishi H, et al. High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population. Eur Heart J Open. 2022;2(3):oeac030.","journal-title":"Eur Heart J Open"},{"issue":"1","key":"23883_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38357-x","volume":"9","author":"H Jang","year":"2019","unstructured":"Jang H, Kang D, Chang Y, Kim Y, Lee JS, Kim KW, et al. Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Sci Rep. 2019;9(1): 1814.","journal-title":"Sci Rep"},{"issue":"1","key":"23883_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01064-x","volume":"19","author":"HH Lee","year":"2020","unstructured":"Lee HH, Cho Y, Choi YJ, Huh BW, Lee BW, Kang ES, et al. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovasc Diabetol. 2020;19(1): 81.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"23883_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101416","volume":"49","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Csermely A, Taverna A, Cappelli D, Benfari G, Bonapace S, et al. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. Diabetes Metab. 2023;49(2): 101416.","journal-title":"Diabetes Metab"},{"issue":"11","key":"23883_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13855","volume":"52","author":"Z Yan","year":"2022","unstructured":"Yan Z, Liu Y, Li W, Zhao X, Lin W, Zhang J, et al. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: a systematic review and meta-analysis. Eur J Clin Invest. 2022;52(11): e13855.","journal-title":"Eur J Clin Invest"},{"key":"23883_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2023.04.26.23289177","author":"A Ahmad","year":"2023","unstructured":"Ahmad A, Lim LL, Morieri ML, Tam CH, Cheng F, Chikowore T, et al. Precision prognostics for cardiovascular disease in type 2 diabetes: a systematic review and meta-analysis. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.04.26.23289177.","journal-title":"medRxiv"},{"key":"23883_CR17","doi-asserted-by":"crossref","unstructured":"Lo Ck Fau -, Mertz D, Mertz D, Fau - Loeb M, Loeb M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014(14):45.","DOI":"10.1186\/1471-2288-14-45"},{"key":"23883_CR18","unstructured":"Atkins D, Fau - Best D, Best D, Fau - Briss PA, Briss Pa Fau -, Eccles M, Eccles M, Fau - Falck-Ytter Y, Falck-Ytter Y, Fau - Flottorp S, Flottorp S, Fau - Guyatt GH et al. Grading quality of evidence and strength of recommendations. BMJ. 2004((7454):1490):328."},{"issue":"7650","key":"23883_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman Ad. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"3","key":"23883_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/XEB.0000000000000132","volume":"16","author":"C Xu","year":"2018","unstructured":"Xu C, Doi SAR. The robust error meta-regression method for dose-response meta-analysis. International Journal of Evidence-Based Healthcare. 2018;16(3):138\u201344.","journal-title":"International Journal of Evidence-Based Healthcare"},{"issue":"2","key":"23883_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jebm.12267","volume":"11","author":"C Zhang","year":"2018","unstructured":"Zhang C, Jia P, Yu L, Xu C. Introduction to methodology of dose-response meta-analysis for binary outcome: with application on software. J Evid Based Med. 2018;11(2):125\u20139.","journal-title":"J Evid Based Med"},{"key":"23883_CR22","doi-asserted-by":"crossref","unstructured":"Wilker EH, Osman M, Weisskopf MA-O. Ambient air pollution and clinical dementia: systematic review and meta-analysis. BMJ. 2023;381:e071620.","DOI":"10.1136\/bmj-2022-071620"},{"key":"23883_CR23","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"23883_CR24","unstructured":"Higgins JP. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. 2022."},{"key":"23883_CR25","doi-asserted-by":"publisher","unstructured":"Xiong S, Yin S, Deng W, Zhao Y, Li W, Wang P, et al. Predictive value of liver fibrosis scores in cardiovascular diseases among hypertensive population. J Hypertens. 2023;41(5):741\u201350. https:\/\/doi.org\/10.1097\/HJH.0000000000003394.","DOI":"10.1097\/HJH.0000000000003394"},{"issue":"1","key":"23883_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-02020-z","volume":"21","author":"N Akuta","year":"2021","unstructured":"Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, et al. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. BMC Gastroenterol. 2021;21(1): 434.","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"23883_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/hep4.1105","volume":"1","author":"T Tada","year":"2017","unstructured":"Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Akita T, et al. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2017;1(9):899\u2013910.","journal-title":"Hepatol Commun"},{"issue":"12","key":"23883_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277729","volume":"17","author":"SW Choi","year":"2022","unstructured":"Choi SW, Kweon SS, Lee YH, Ryu SY, Nam HS, Shin MH. Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: the Dong-gu study. PLoS One. 2022;17(12): e0277729.","journal-title":"PLoS One"},{"issue":"7","key":"23883_CR29","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.cgh.2017.11.026","volume":"16","author":"YC Hwang","year":"2018","unstructured":"Hwang YC, Ahn HY, Park SW, Park CY. Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men. Clin Gastroenterol Hepatol. 2018;16(7):1131-e75.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"23883_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.dld.2020.10.014","volume":"53","author":"Y Schonmann","year":"2021","unstructured":"Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53(1):79\u201385.","journal-title":"Dig Liver Dis"},{"key":"23883_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.03.025","author":"N Shibata","year":"2024","unstructured":"Shibata N, Ito T, Toyoda H, Tanaka A, Morita Y, Kanzaki Y, et al. Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2024. https:\/\/doi.org\/10.1016\/j.numecd.2024.03.025.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"23883_CR32","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/j.numecd.2024.09.001","volume":"34","author":"JW Baek","year":"2024","unstructured":"Baek JW, Yang YS, Jung KJ, Kimm H, Kim SY, Lee S, et al. Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: a prospective cohort study. Nutr Metab Cardiovasc Dis. 2024;34(12):2623\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"23883_CR33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.124.24252","volume":"82","author":"Y Huang","year":"2025","unstructured":"Huang Y, Wan T, Hong Y, Wang X, Jiang X, Yang \u6768\u6d0b Y, et al. Impact of NAFLD and fibrosis on adverse cardiovascular events in patients with hypertension. Hypertension. 2025;82(6):1012\u201323.","journal-title":"Hypertension"},{"key":"23883_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3677","author":"N Sasaki","year":"2025","unstructured":"Sasaki N, Ueno Y, Ozono R, Nakano Y, Higashi Y. Association between liver fibrosis, plasma volume status, and cardiovascular mortality: the Hiroshima study on glucose metabolism and cardiovascular diseases. Eur J Heart Fail. 2025. https:\/\/doi.org\/10.1002\/ejhf.3677.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"23883_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.dld.2019.01.017","volume":"51","author":"A De Vincentis","year":"2019","unstructured":"De Vincentis A, Costanzo L, Vespasiani-Gentilucci U, Picardi A, Bandinelli S, Ferrucci L, et al. Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. Dig Liver Dis. 2019;51(9):1330\u20136.","journal-title":"Dig Liver Dis"},{"key":"23883_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100780","author":"QM Anstee","year":"2024","unstructured":"Anstee QM, Berentzen TL, Nitze LM, Jara M, Jensen AB, Kj\u00e6r MS, et al. Prognostic utility of Fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur. 2024. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100780.","journal-title":"Lancet Reg Health Eur"},{"key":"23883_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.045","author":"TJ Hydes","year":"2024","unstructured":"Hydes TJ, Kennedy OJ, Glyn-Owen K, Buchanan R, Parkes J, Cuthbertson DJ, et al. Liver fibrosis assessed via non-invasive tests is associated with incident heart failure in a general population cohort. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.045.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"23883_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.26156","volume":"57","author":"D Kim","year":"2013","unstructured":"Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the united States. Hepatology. 2013;57(4):1357\u201365.","journal-title":"Hepatology"},{"issue":"3","key":"23883_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","volume":"117","author":"J Vieira Barbosa","year":"2022","unstructured":"Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, et al. Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol. 2022;117(3):453\u201361.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"23883_CR40","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1111\/jgh.15523","volume":"36","author":"G Pennisi","year":"2021","unstructured":"Pennisi G, Di Marco V, Buscemi C, Mazzola G, Randazzo C, Spatola F, et al. Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. J Gastroenterol Hepatol (Australia). 2021;36(9):2389\u201396.","journal-title":"J Gastroenterol Hepatol (Australia)"},{"issue":"9","key":"23883_CR41","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/apt.16324","volume":"53","author":"JG Park","year":"2021","unstructured":"Park JG, Jung J, Verma KK, Kang MK, Madamba E, Lopez S, et al. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;53(9):1030\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"23883_CR42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/apt.15660","volume":"51","author":"JB Henson","year":"2020","unstructured":"Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"23883_CR43","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/MEG.0000000000002462","volume":"34","author":"M Yi","year":"2022","unstructured":"Yi M, Peng W, Teng F, Kong Q, Chen Z. The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022;34(12):1277\u201384.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"23883_CR44","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/HJH.0000000000003394","volume":"41","author":"S Xiong","year":"2023","unstructured":"Xiong S, Yin S, Deng W, Zhao Y, Li W, Wang P, et al. Predictive value of liver fibrosis scores in cardiovascular diseases among hypertensive population. J Hypertens. 2023;41(5):741\u201350.","journal-title":"J Hypertens"},{"issue":"1","key":"23883_CR45","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/07853890.2021.1943514","volume":"53","author":"C-O Lee","year":"2021","unstructured":"Lee C-O, Li H-L, Tsoi M-F, Cheung C-L, Cheung BMY. Association between the liver fat score (LFS) and cardiovascular diseases in the National health and nutrition examination survey 1999\u20132016. Ann Med. 2021;53(1):1067\u201375.","journal-title":"Ann Med"},{"issue":"5","key":"23883_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13811","volume":"22","author":"J Adjei-Mosi","year":"2023","unstructured":"Adjei-Mosi J, Sun Q, Smithson SB, Shealy GL, Amerineni KD, Liang Z, et al. Age-dependent loss of hepatic SIRT1 enhances NLRP3 inflammasome signaling and impairs capacity for liver fibrosis resolution. Aging Cell. 2023;22(5): e13811.","journal-title":"Aging Cell"},{"issue":"11","key":"23883_CR47","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41569-023-00881-3","volume":"20","author":"M Abdellatif","year":"2023","unstructured":"Abdellatif M, Rainer PP, Sedej S, Kroemer G. Hallmarks of cardiovascular ageing. Nat Rev Cardiol. 2023;20(11):754\u201377.","journal-title":"Nat Rev Cardiol"},{"key":"23883_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110497","volume":"121","author":"H Tao","year":"2023","unstructured":"Tao H, Liu Q, Zeng A, Song L. Unlocking the potential of mesenchymal stem cells in liver fibrosis: insights into the impact of autophagy and aging. Int Immunopharmacol. 2023;121: 110497.","journal-title":"Int Immunopharmacol"},{"key":"23883_CR49","doi-asserted-by":"publisher","unstructured":"Wong ND, Bang M, Fan W, Espinueva A. Liver fibrosis and associated cardiovascular disease risk and its predictors among US adults with and without diabetes. Circulation. 2020;142(SUPPL 3). https:\/\/doi.org\/10.1161\/circ.142.suppl_3.17098.","DOI":"10.1161\/circ.142.suppl_3.17098"},{"key":"23883_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000351","author":"G Pennisi","year":"2023","unstructured":"Pennisi G, Enea M, Falco V, Aithal GP, Palaniyappan N, Yilmaz Y, et al. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000351.","journal-title":"Hepatology"},{"issue":"10","key":"23883_CR51","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.2337\/dc22-0556","volume":"45","author":"RG Kim","year":"2022","unstructured":"Kim RG, Deng J, Reaso JN, Grenert JP, Khalili M. Noninvasive fibrosis screening in fatty liver disease among vulnerable populations: impact of diabetes and obesity on FIB-4 score accuracy. Diabetes Care. 2022;45(10):2449\u201351.","journal-title":"Diabetes Care"},{"key":"23883_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11010098","author":"S Ballestri","year":"2021","unstructured":"Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics. 2021. https:\/\/doi.org\/10.3390\/diagnostics11010098.","journal-title":"Diagnostics"},{"issue":"22","key":"23883_CR53","doi-asserted-by":"publisher","first-page":"e035371","DOI":"10.1161\/JAHA.123.035371","volume":"13","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang HJ, Fang CC, Li L, Lai ZQ, Liang NP, et al. Association between noninvasive liver fibrosis scores and heart failure in a general population. J Am Heart Assoc. 2024;13(22):e035371.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"23883_CR54","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.cgh.2024.03.045","volume":"22","author":"TJ Hydes","year":"2024","unstructured":"Hydes TJ, Kennedy OJ, Glyn-Owen K, Buchanan R, Parkes J, Cuthbertson DJ, et al. Liver fibrosis assessed via noninvasive tests is associated with incident heart failure in a general population cohort. Clin Gastroenterol Hepatol. 2024;22(8):1657\u201367.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"23883_CR55","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/hepr.13508","volume":"50","author":"S Oeda","year":"2020","unstructured":"Oeda S, Takahashi H, Imajo K, Seko Y, Kobayashi T, Ogawa Y, et al. Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: comparison between M and XL probes. Hepatol Res. 2020;50(7):831\u20139.","journal-title":"Hepatol Res"},{"issue":"2","key":"23883_CR56","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/liv.15801","volume":"44","author":"J Boeckmans","year":"2024","unstructured":"Boeckmans J, Sandrin L, Knackstedt C, Schattenberg JM. Liver stiffness as a cornerstone in heart disease risk assessment. Liver Int. 2024;44(2):344\u201356.","journal-title":"Liver Int"},{"issue":"11","key":"23883_CR57","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903\u201313.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23883-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-23883-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23883-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:39:04Z","timestamp":1757417944000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-23883-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23883"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-23883-x","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2747"}}